T. Rowe Price Associates »

Summit Therapeutics shares owned by T. Rowe Price Associates

Quarter-by-quarter ownership of Summit Therapeutics (SMMT) shares owned by T. Rowe Price Associates from 13F filings

Historical chart of T. Rowe Price Associates investment in Summit Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Summit Therapeutics held by T. Rowe Price Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Summit Therapeutics by T. Rowe Price Associates

Quarter filed Position value Share count Share price at filing
2023-12-31 $74k 28k 2.64
2023-09-30 $51k 27k 1.89
2023-06-30 $60k 24k 2.55

More positions owned by T. Rowe Price Associates

Microsoft Corp Comm Stk (MSFT)
Apple Comm Stk (AAPL)
Amazon Comm Stk (AMZN)
Nvidia Corporation Comm Stk (NVDA)
Meta Platforms Comm Stk (META)
Alphabet Comm Stk (GOOGL)
Alphabet Comm Stk (GOOG)
Unitedhealth Group Comm Stk (UNH)
Eli Lilly & Co Comm Stk (LLY)
Visa Comm Stk (V)
Mastercard Incorporated Comm Stk (MA)
Tesla Comm Stk (TSLA)
Intuit Comm Stk (INTU)
Servicenow Comm Stk (NOW)
Fiserv Comm Stk (FI)

View all positions for T. Rowe Price Associates

Top funds holding Summit Therapeutics

Vanguard Group
Charles Schwab Investment Management
Steward Partners Investment Advisory
ALPS Advisors
Barclays
Bank of New York Mellon
Jpmorgan Chase & Co
Swiss National Bank
Goldman Sachs Group
UBS Group
Advisor Group Holdings
China Universal Asset Management
Rhumbline Advisers
CSS
Bank of America Corporation

View all funds holding Summit Therapeutics